Ginkgo Bioworks Holdings Stock Alpha and Beta Analysis
| DNA Stock | USD 8.31 0.16 1.96% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Ginkgo Bioworks Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Ginkgo Bioworks over a specified time horizon. Remember, high Ginkgo Bioworks' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Ginkgo Bioworks' market risk premium analysis include:
Beta 2.58 | Alpha (0.52) | Risk 5.36 | Sharpe Ratio (0.17) | Expected Return (0.92) |
Ginkgo Bioworks Quarterly Cash And Equivalents |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Ginkgo Bioworks Backtesting, Ginkgo Bioworks Valuation, Ginkgo Bioworks Correlation, Ginkgo Bioworks Hype Analysis, Ginkgo Bioworks Volatility, Ginkgo Bioworks History and analyze Ginkgo Bioworks Performance. Ginkgo Bioworks Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Ginkgo Bioworks market risk premium is the additional return an investor will receive from holding Ginkgo Bioworks long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Ginkgo Bioworks. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Ginkgo Bioworks' performance over market.| α | -0.52 | β | 2.58 |
Ginkgo Bioworks expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Ginkgo Bioworks' Buy-and-hold return. Our buy-and-hold chart shows how Ginkgo Bioworks performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Ginkgo Bioworks Market Price Analysis
Market price analysis indicators help investors to evaluate how Ginkgo Bioworks stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Ginkgo Bioworks shares will generate the highest return on investment. By understating and applying Ginkgo Bioworks stock market price indicators, traders can identify Ginkgo Bioworks position entry and exit signals to maximize returns.
Ginkgo Bioworks Return and Market Media
The median price of Ginkgo Bioworks for the period between Fri, Oct 3, 2025 and Thu, Jan 1, 2026 is 9.56 with a coefficient of variation of 24.85. The daily time series for the period is distributed with a sample standard deviation of 2.71, arithmetic mean of 10.91, and mean deviation of 2.47. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Ginkgo Bioworks Holdings, Inc. Stock Dips While Market Gains Key Facts | 10/28/2025 |
2 | Ginkgo Bioworks Stock Plummets Following Q3 Estimates Miss, Reaffirms FY2025 Outlook Below Consensus | 11/07/2025 |
3 | Disposition of 1061 shares by Mark Dmytruk of Ginkgo Bioworks subject to Rule 16b-3 | 11/28/2025 |
4 | Disposition of 1244 shares by Mark Dmytruk of Ginkgo Bioworks at 7.283 subject to Rule 16b-3 | 12/01/2025 |
5 | DNASTONE NAMES JESS WATTS FIRST-EVER CHIEF STRATEGY OFFICER | 12/02/2025 |
6 | DNA Detectives Expose Massive Illegal Shark Trade In Hong Kong | 12/03/2025 |
7 | Ginkgo Bioworks Selected by PNNL to Deliver a Modular, HighThroughput Phenotyping Platform for DOEs M2PC | 12/05/2025 |
8 | Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety | 12/09/2025 |
9 | ProteoNic 2G UNic Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies | 12/11/2025 |
10 | Disposition of 312 shares by Coen Steven P. of Ginkgo Bioworks subject to Rule 16b-3 | 12/12/2025 |
11 | DNASTONE CHAMPIONS RADICAL EMPATHY WITH HUNGRY WEEKEND CAMPAIGN TO SUPPORT BACKPACK BRIGADE AND END WEEKEND HUNGER | 12/15/2025 |
12 | Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment | 12/17/2025 |
13 | Ginkgo Bioworks Shares Rise On New Cancer Screening Approach Plans | 12/22/2025 |
14 | Ginkgo Bioworks Holdings Insider Sellers Miss The Bus As Stock Jumps 10.0 | 12/26/2025 |
About Ginkgo Bioworks Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Ginkgo or other stocks. Alpha measures the amount that position in Ginkgo Bioworks Holdings has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 64.2 | 25.98 | 36.08 | 34.28 | PTB Ratio | 1.63 | 2.99 | 0.71 | 0.68 |
Ginkgo Bioworks Upcoming Company Events
As portrayed in its financial statements, the presentation of Ginkgo Bioworks' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ginkgo Bioworks' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Ginkgo Bioworks' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Ginkgo Bioworks. Please utilize our Beneish M Score to check the likelihood of Ginkgo Bioworks' management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Ginkgo Bioworks
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Ginkgo Bioworks Backtesting, Ginkgo Bioworks Valuation, Ginkgo Bioworks Correlation, Ginkgo Bioworks Hype Analysis, Ginkgo Bioworks Volatility, Ginkgo Bioworks History and analyze Ginkgo Bioworks Performance. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Ginkgo Bioworks technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.